Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Lundbeck Japan Plans to Double Workforce by 2028 as It Eyes 3 Drug Approvals
Lundbeck Japan is poised for a major scale-up, with plans to roughly double its headcount from about 100 to around 200 employees by the end of 2028. President Rune Ejler Andersen says that the expansion is designed to support the…
To read the full story
Related Article
- Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan
November 18, 2025
- As Trintellix Debut Nears, Lundbeck Japan Morphing into Full-Fledged Commercial Company
November 7, 2019
BUSINESS
- Eisai Maps Out Next-Gen Alzheimer’s Strategy beyond Leqembi
August 18, 2026
- Enhertu Hits PIII Primary Goal in 1st-Line HER2-Mutant NSCLC
August 18, 2026
- Enhertu Combo Scores China Nod in 1st-Line HER2 Breast Cancer
August 18, 2026
- Santen Releases Glaucoma Drug Rhopressa in Japan
August 18, 2026
- Yaz AGs Now Available in Japan, Hisamitsu Handling Distribution
August 18, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…